Experimental drug TAK-243 targets tough blood cancers in early trial
NCT ID NCT03816319
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-243
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat blood cancers that have stopped responding to standard therapy.
What could go wrong
This is a very early (Phase 1) trial that is currently suspended, so results are uncertain. The drug may not work or may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States